Overview

Use of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% for Allergic Conjunctivitis and Contact Lenses

Status:
Unknown status
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess if BEPREVE (bepotastine besilate ophthalmic solution) 1.5% will have an effect on contact lens wear in patients with contact lens intolerance due to allergic conjunctivitis.
Phase:
Phase 4
Details
Lead Sponsor:
Hom, Milton M., OD, FAAO
Collaborator:
Bausch & Lomb Incorporated
Treatments:
Bepotastine besilate
Ophthalmic Solutions